NEW CASTLE, Del., Sept. 24, 2025 /PRNewswire/ -- IgniteData, the healthtech company behind Archer—an advanced EHR-to-EDC solution delivering fully automated, regulatory-grade…
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every…
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved…
The Company will provide an update on its novel Doxorubicin containing Microneedle Array (D-MNA) treatment to non-invasively treat basal cell…
FRAMINGHAM, Mass., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Alira Health announced today that it has become the first Platinum CRO…
VICTORIA, British Columbia, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology…
Data highlights ability of Akari’s ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for…
Sapu003 Designed to Overcome Limitations of Afinitor®, FDA-Approved Oral Everolimus, by Delivering Full Strength of the Drug via Intravenous InjectionSAN…
Funding supports Phase 2b development of clofutriben, a novel HSD-1 inhibitor, with a focus on cortisol-driven metabolic dysfunction in type…
BOSTON, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company…